An updated pocket card on atherosclerotic cardiovascular disease (ASCVD) for pharmacy and medical students: targets, antiplatelets, lipid-lowering, other heart-protective drugs, angina relief, and stroke and PAD essentials, based on the 2025 ACC/AHA ACS guideline, the 2024 ESC chronic coronary syndromes guideline and the 2026 lipid guideline.
ASCVD Pocket Card 2026
Secondary prevention of heart attack, stroke and PAD · based on 2025 ACC/AHA ACS, 2024 ESC CCS and 2026 lipid guidelines
All for almost every ASCVD patient Select for selected patients Avoid avoid or caution | ASCVD = atherosclerotic cardiovascular disease · OD = once daily · BD = twice daily
What counts as ASCVD & targets
- ASCVD: heart attack or ACS, stable angina, stent or bypass, ischaemic stroke or TIA, peripheral artery disease (PAD), atherosclerotic aortic disease
- LDL-C: under 55 mg/dL (1.4 mmol/L) and at least 50% lower than baseline; non-HDL under 85
- Blood pressure: under 130/80; systolic under 120 if tolerated
- Diabetes: HbA1c under 7% for most; use drugs with heart benefit
- Lifestyle: stop smoking completely, 150 min/week activity, Mediterranean-style diet, healthy weight, cardiac rehab after MI or stent
- Vaccines: yearly flu vaccine
Antiplatelets
- All Aspirin: 75 to 100 mg OD lifelong (300 mg chewed at the start of a heart attack)
- All Clopidogrel: 75 mg OD if aspirin is not tolerated; preferred single antiplatelet in PAD and after stroke for many
- After ACS: DAPT: aspirin + a P2Y12 inhibitor for 12 months if bleeding risk is not high
- Select Ticagrelor: 180 mg load, then 90 mg BD; keep aspirin at 100 mg or less; can cause breathlessness
- Select Prasugrel: 60 mg load, then 10 mg OD (5 mg if under 60 kg or 75 years or older); never after stroke/TIA
- Select Clopidogrel in ACS: 300 to 600 mg load, then 75 mg OD; when ticagrelor/prasugrel unsuitable or with anticoagulant
- Bleeding risk: add a PPI; after 1 month on ticagrelor DAPT, can switch to ticagrelor alone
Lipid-lowering
- All High-intensity statin: atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg; start in hospital after ACS
- Select Add ezetimibe 10 mg: if LDL not at goal; after ACS can start statin + ezetimibe together
- Select Add PCSK9 drug, inclisiran or bempedoic acid: if LDL still 70 mg/dL or more on max statin (2025 ACS guideline), aiming for under 55
- Select Icosapent ethyl: 2 g BD if triglycerides 150 to 499 on a statin
- Check: lipids 4 to 8 weeks after starting or changing, then every 6 to 12 months
Other heart-protective drugs
- Select Beta-blocker: after MI with EF under 50%, or for angina or arrhythmia (bisoprolol, metoprolol, carvedilol); routine long-term use with normal EF is no longer needed for most
- Select ACEi or ARB: with hypertension, diabetes, CKD, or EF 40% or less (ramipril 10 mg, perindopril 8 mg)
- Select SGLT2i or GLP-1 RA: type 2 diabetes with ASCVD, whatever the HbA1c
- Select Semaglutide 2.4 mg: overweight or obesity without diabetes: 20% fewer heart attacks and strokes (SELECT)
- Select Rivaroxaban 2.5 mg BD + aspirin: stable CAD or PAD with high clot risk and low bleeding risk (COMPASS)
- Select Colchicine 0.5 mg OD: may be considered in stable CAD to reduce inflammation (ESC 2024); not with severe CKD or strong CYP3A4 inhibitors
Angina relief
- GTN spray 400 micrograms: under the tongue, sitting down; repeat after 5 min; call Rescue 1122 if pain is not better 5 min after the first dose
- First-line: beta-blocker or calcium channel blocker (amlodipine; diltiazem or verapamil if no HF and no beta-blocker)
- Second-line: long-acting nitrate (isosorbide mononitrate 30 to 60 mg OD), ranolazine, ivabradine, nicorandil, trimetazidine
- Nitrate-free gap: 8 to 12 hours each day to prevent tolerance
- Avoid Sildenafil, tadalafil: with any nitrate: severe low BP
Stroke & PAD specifics
- Minor stroke / high-risk TIA: aspirin + clopidogrel for 21 days, then one antiplatelet
- Stroke from atrial fibrillation: DOAC (apixaban, rivaroxaban, dabigatran, edoxaban), not antiplatelets
- After stroke: statin to LDL under 70 (lower if coronary disease too); BP under 130/80
- PAD: antiplatelet (clopidogrel or aspirin) + high-intensity statin; supervised walking exercise
- Claudication: cilostazol 100 mg BD (not in heart failure)
- Avoid NSAIDs: raise heart attack, stroke and bleeding risk
Typical adult doses. Antiplatelet choice and duration after a stent are decided by the cardiologist. Always follow local guidelines and the prescriber. Sources: 2025 ACC/AHA ACS Guideline; 2024 ESC Chronic Coronary Syndromes Guidelines; 2026 ACC/AHA Dyslipidemia Guideline; AHA/ASA stroke and ACC/AHA PAD guidelines.
Details behind the card
1. What changed recently?
- ACS (2025 ACC/AHA): dual antiplatelet therapy for at least 12 months if bleeding risk is not high; ticagrelor or prasugrel preferred over clopidogrel in patients having PCI.
- Less bleeding: a PPI for people at risk of stomach bleeding, switching to ticagrelor alone at least 1 month after PCI in suitable patients, and stopping aspirin 1 to 4 weeks after PCI in people who need long-term anticoagulation.
- Lipids after ACS: add a non-statin drug (ezetimibe, PCSK9 antibody, inclisiran or bempedoic acid) if LDL stays 70 mg/dL or more on the maximum tolerated statin.
- Diabetes and obesity: SGLT2 inhibitors and GLP-1 RAs with heart benefit are recommended in type 2 diabetes with coronary disease; semaglutide reduces events in obesity without diabetes.
- Beta-blockers: recent trials found little benefit from routine long-term use after MI when heart function is normal; they remain important when EF is reduced, or for angina and arrhythmias.
2. Antiplatelet drugs compared
| Drug | How it works | Dose | Key points |
|---|---|---|---|
| Aspirin | Irreversibly blocks COX-1, less thromboxane A2 | 75 to 100 mg OD | Stomach ulcers and bleeding; avoid in true aspirin allergy |
| Clopidogrel | P2Y12 blocker (prodrug, activated by CYP2C19) | 75 mg OD | Weaker in CYP2C19 poor metabolisers; avoid omeprazole/esomeprazole, prefer pantoprazole |
| Prasugrel | P2Y12 blocker, stronger and more reliable | 10 mg OD (5 mg if under 60 kg or 75+ years) | Contraindicated after stroke/TIA; more bleeding |
| Ticagrelor | Reversible P2Y12 blocker (not a prodrug) | 90 mg BD after ACS; 60 mg BD long term | Breathlessness, bleeding; aspirin must be 100 mg or less; CYP3A4 interactions |
| Rivaroxaban (vascular dose) | Factor Xa inhibitor | 2.5 mg BD with aspirin | Only for stable CAD/PAD with low bleeding risk |
3. Heart attack: what patients should know
- Chest pain over 15 minutes, pain spreading to arm, jaw or back, sweating or breathlessness: call Rescue 1122 straight away.
- Chew aspirin 300 mg (unless allergic) while waiting for help.
- Never stop aspirin or a P2Y12 inhibitor on your own, especially in the first year after a stent: stent thrombosis can be fatal.
- Tell your dentist or surgeon about antiplatelets; most dental work can be done without stopping them.
- Attend cardiac rehabilitation: it lowers death and readmission.
4. Stopping smoking
- Smoking cessation is one of the most powerful treatments after a heart attack: risk falls quickly after quitting.
- Varenicline (0.5 mg OD for 3 days, 0.5 mg BD for 4 days, then 1 mg BD for 12 weeks) is the most effective medicine.
- Nicotine replacement (patch plus gum or lozenge) is safe in heart disease.
- Combine medicine with counselling; avoid all tobacco including naswar, huqqa and shisha.
5. Drug interactions to watch
- Clopidogrel with omeprazole or esomeprazole: reduced effect; use pantoprazole.
- Ticagrelor with clarithromycin, ketoconazole or ritonavir: higher bleeding risk; avoid.
- Simvastatin or atorvastatin with clarithromycin: muscle damage; hold the statin during the antibiotic.
- Antiplatelets with NSAIDs, SSRIs or anticoagulants: more bleeding; add a PPI and review need.
- Colchicine with clarithromycin, verapamil or diltiazem: colchicine toxicity.
Remember for exams
- Every ASCVD patient: antiplatelet, high-intensity statin, BP and lifestyle control.
- LDL goal in ASCVD: under 55 mg/dL and 50% reduction.
- After ACS: DAPT for 12 months; ticagrelor or prasugrel preferred for PCI.
- Prasugrel is contraindicated after stroke/TIA; ticagrelor needs aspirin 100 mg or less.
- Clopidogrel: avoid omeprazole; use pantoprazole.
- Never give nitrates with sildenafil or tadalafil.
Sources
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes. Circulation / JACC, February 2025.
- 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal 2024;45:3415-3537.
- 2026 ACC/AHA Guideline on the Management of Dyslipidemia.
- AHA/ASA guideline on secondary stroke prevention; ACC/AHA guideline on lower extremity PAD.
- Product information (SmPC) for individual drugs.
Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards
No comments:
Post a Comment